Prudential Financial
KYTX icon

Prudential Financial’s Kyverna Therapeutics KYTX Stock Holding History

Prudential Financial’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-39,570
Closed -$193K – 2784
2024
Q3 		$193K Buy
+39,570
New +$305K ﹤0.01% 2518
2024
Q2 		– Sell
-11,500
Closed -$286K – 2803
2024
Q1 		$286K Buy
+11,500
New +$321K ﹤0.01% 2355

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Prudential Financial's KYTX Position: Q4 2024 in Review

Prudential Financial sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 39,570 shares — an estimated $193K sold.

Prudential Financial first reported a position in KYTX in Q1 2024 and held it in 2 quarters. The position peaked at $286K in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • Prudential Financial reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Prudential Financial sold 39,570 Kyverna Therapeutics shares in Q4 2024, an estimated $193K.
  • Prudential Financial first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 2 quarters.
  • Prudential Financial's Kyverna Therapeutics position peaked at $286K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on Prudential Financial's 13F filing for Q4 2024, filed 11 Feb 2025.